November 2026 Biotech Catalysts: 12 FDA Dates & Phase 3 Readouts

Phase 3 data readout for suzetrigine in diabetic peripheral neuropathy

Suzetrigine · Diabetic peripheral neuropathy (DPN)

Vertex's suzetrigine is a non-opioid, selective NaV1.8 pain signal inhibitor that has already shown promise in acute pain. This Phase 3 trial tests it in diabetic peripheral neuropathy, a chronic nerve pain condition affecting millions. Positive results could position suzetrigine as a first-in-class chronic pain treatment, offering an alternative to opioids and gabapentinoids.

The trial's primary endpoint is change in pain score over 12 weeks. If results are statistically significant and clinically meaningful, Vertex could file for approval in 2027, and the stock may rise. However, chronic pain trials have high placebo responses; failure would be a setback, but Vertex's pipeline is diversified.

Sponsor record: 17 of 156 late-stage studies registered by Vertex Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for vutrisiran in ATTR amyloidosis with cardiomyopathy

Vutrisiran · Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)

Vutrisiran is an RNAi therapeutic that silences transthyretin production, reducing amyloid deposits. This Phase 3 HELIOS-B trial tests it in ATTR-CM, a progressive heart condition. Positive results could expand vutrisiran's label beyond polyneuropathy, making it a blockbuster. The study is event-driven, and results are highly anticipated.

The trial's primary endpoint is a composite of all-cause mortality and recurrent cardiovascular events. If vutrisiran shows a significant benefit, it could become a standard of care, and Alnylam's stock may surge. However, competition from Pfizer's tafamidis and other drugs exists. Failure would be a major blow.

Sponsor record: 6 of 45 late-stage studies registered by Alnylam Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for orforglipron in obesity

Orforglipron · Obesity

Orforglipron is an oral GLP-1 receptor agonist being developed for obesity. Unlike injectable drugs like semaglutide, it is a small molecule that can be taken as a pill, potentially offering a more convenient option. This Phase 3 trial (ATTAIN-1) will measure weight loss over 72 weeks. Results could reshape the obesity market.

If orforglipron shows weight loss comparable to injectable GLP-1s (15-20%), it could be a game-changer. Lilly's stock may rise, but safety (liver enzyme elevations) and tolerability (GI side effects) will be scrutinized. Failure would be a setback, but Lilly has other obesity drugs like tirzepatide.

Sponsor record: 94 of 1074 late-stage studies registered by Eli Lilly were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

FDA Advisory Committee meeting for lecanemab in early Alzheimer's disease

Lecanemab · Early Alzheimer's disease

Lecanemab is an anti-amyloid antibody that reduces amyloid plaques and slows cognitive decline in early Alzheimer's. The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will review the data and vote on whether the benefits outweigh the risks, including brain swelling and bleeding. This is a critical step toward full approval.

The committee's vote is non-binding but influential. Given the positive Phase 3 Clarity AD results and prior accelerated approval, a favorable vote is likely. However, safety concerns may lead to a narrow vote. Biogen's stock may react to the vote, but the final FDA decision is expected in January 2027.

Sponsor record: 66 of 205 late-stage studies registered by Biogen were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for mRNA-4157 (personalized cancer vaccine) in melanoma

mRNA-4157 · Adjuvant treatment of high-risk melanoma

mRNA-4157 is a personalized cancer vaccine that encodes up to 34 neoantigens specific to a patient's tumor. It is being tested in combination with Keytruda (pembrolizumab) as an adjuvant therapy for resected high-risk melanoma. The Phase 3 trial (KEYNOTE-942) is evaluating recurrence-free survival. Positive results could herald a new era of personalized cancer treatment.

The trial is event-driven, and results are expected in late 2026. If the vaccine shows a significant improvement in recurrence-free survival over Keytruda alone, it could become a standard of care. Moderna's stock may surge, but manufacturing complexity and cost are concerns. Failure would be a major setback for the platform.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for olpasiran in cardiovascular disease

Olpasiran · Atherosclerotic cardiovascular disease (ASCVD) with elevated Lp(a)

Olpasiran is a small interfering RNA (siRNA) that reduces lipoprotein(a) [Lp(a)], a genetic risk factor for heart disease. Elevated Lp(a) affects about 20% of the population, and there are no approved drugs targeting it. This Phase 3 trial (OCEAN(a)-Outcomes) is testing whether lowering Lp(a) reduces cardiovascular events like heart attacks and strokes.

The trial is large and event-driven, with results expected in late 2026. If olpasiran shows a significant reduction in major adverse cardiovascular events, it could become a blockbuster. However, the effect may take years to manifest. Amgen's stock may react positively, but investors should watch for safety signals.

Sponsor record: 75 of 600 late-stage studies registered by Amgen were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for lenacapavir in HIV pre-exposure prophylaxis (PrEP)

Lenacapavir · HIV pre-exposure prophylaxis (PrEP)

Lenacapavir is a long-acting injectable HIV capsid inhibitor. This Phase 3 trial (PURPOSE 1) is evaluating a twice-yearly injection for HIV prevention. If successful, it could offer a highly convenient PrEP option, improving adherence and reducing new infections. Gilead already has oral PrEP drugs, but a long-acting injectable could dominate the market.

The trial is expected to show high efficacy, as lenacapavir has shown potent antiviral activity. If results are positive, Gilead will likely file for regulatory approval. The stock may rise, but competition from other long-acting PrEPs like cabotegravir (ViiV) exists. Safety and injection site reactions will be monitored.

Sponsor record: 97 of 485 late-stage studies registered by Gilead Sciences were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for oral semaglutide (Rybelsus) in obesity

Oral semaglutide · Obesity

Novo Nordisk is testing a higher dose (25mg and 50mg) of oral semaglutide, a GLP-1 receptor agonist, for weight management. Currently, Rybelsus is approved for diabetes at lower doses. This Phase 3 trial (OASIS 1) will evaluate weight loss over 68 weeks. If successful, it could offer an oral alternative to injectable Wegovy.

Results are expected to show significant weight loss, possibly around 15% or more. However, oral semaglutide has lower bioavailability and may have more GI side effects. Approval would expand Novo's obesity franchise, but competition from Lilly's oral orforglipron is a threat. The stock may react moderately.

Sponsor record: 33 of 473 late-stage studies registered by Novo Nordisk were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for datopotamab deruxtecan (Dato-DXd) in non-small cell lung cancer

Datopotamab deruxtecan · Advanced non-small cell lung cancer (NSCLC) after prior therapy

Dato-DXd is an antibody-drug conjugate targeting TROP2, delivering a potent chemotherapy to cancer cells. This Phase 3 trial (TROPION-Lung01) compares it to docetaxel in patients with previously treated advanced NSCLC. Positive results could establish Dato-DXd as a new standard of care in this setting.

The trial's primary endpoints are progression-free survival and overall survival. In an earlier analysis, PFS was met, but OS data are immature. If OS is also positive, the drug could gain approval. However, the benefit may be limited to certain subgroups. AstraZeneca's stock may react positively, but competition from other ADCs exists.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for itepekimab in chronic obstructive pulmonary disease (COPD)

Itepekimab · Chronic obstructive pulmonary disease (COPD)

Itepekimab is an antibody targeting IL-33, a cytokine involved in inflammation. It is being tested in former smokers with COPD, a condition with limited treatment options. This Phase 3 program (AERIFY-1 and AERIFY-2) evaluates its effect on reducing exacerbations. Positive results could provide a new biologic for COPD.

The trials are expected to show a reduction in moderate-to-severe exacerbations. If successful, itepekimab could be a first-in-class treatment for COPD, and Regeneron's stock may rise. However, the effect may be modest, and safety will be assessed. Failure would be a setback, but Regeneron has other pipeline assets.

Sponsor record: 39 of 224 late-stage studies registered by Regeneron Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for niraparib in prostate cancer

Niraparib · Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) mutations

Niraparib is a PARP inhibitor already approved for ovarian cancer. This Phase 3 trial (MAGNITUDE) tests it in combination with abiraterone for mCRPC patients with HRR mutations. The study aims to show improved radiographic progression-free survival. Positive results could expand niraparib's label and offer a new option for prostate cancer.

The trial has already shown a benefit in the HRR-mutant subgroup, and the readout may confirm this. If positive, J&J could file for approval. The stock impact may be modest as niraparib is not a major growth driver. However, competition from other PARP inhibitors like olaparib exists.

Unverified — date is AI-generated and has not been checked against a primary source.

Phase 3 readout for efgartigimod in primary immune thrombocytopenia (ITP)

Efgartigimod · Primary immune thrombocytopenia (ITP)

Efgartigimod is an FcRn blocker that reduces pathogenic IgG antibodies. It is already approved for generalized myasthenia gravis. This Phase 3 trial (ADVANCE-SC) tests a subcutaneous formulation in chronic ITP, a bleeding disorder. Positive results could expand its use to a new indication.

The trial's primary endpoint is sustained platelet count response. If successful, efgartigimod could become a new treatment option for ITP. Argenx's stock may react positively, but the market is competitive with TPO receptor agonists. Safety and convenience will be key.

Sponsor record: 7 of 57 late-stage studies registered by Argenx were stopped early. Trials stop for many reasons — see the company profile for each one.

Unverified — date is AI-generated and has not been checked against a primary source.